Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
about a third of adults with diabetes also have chronic kidney disease, according to the U.S. Centers for Disease Control and PreventionThe clinical trial tested the efficacy of Ozempic when added ...